RPS6KB1 and neoplasm: This mechanism might have positive anti-tumor effects, since MAP3K1 induction following AZD5363 and AZD8835 administration would elicit (via JNK) IRS1 Ser312 phosphorylation and IRS1 degradation and thereby oppose counteracting signals in response to PI3K pathway inhibition such as from the p70S6K feed-back loop [25].